Teneobio

TeneoBio, Inc. is a biotechnology company developing a new class of biologics—human heavy-chain antibodies (UniAbs™)—for the treatment of cancer, autoimmune diseases, and infectious diseases. TeneoBio has multiple preclinical development products for the treatment of multiple myeloma, prostate cancer, immune system disorders, and AIDS. The lead candidate is a T-cell engager targeting various tumor types, including TNB-383B, a CD3/BCMA bispecific antibody currently in Phase 1 for the treatment of multiple myeloma.